CBD

CBD is FDA-approved as Epidiolex for Lennox-Gastaut and Dravet syndromes, supported by randomized controlled trials. Preclinical evidence suggests neuroprotective, anti-inflammatory, and anxiolytic effects, but clinical evidence for most non-epilepsy indications remains limited and mixed. Studies on chronic pain in older adults show inconsistent results, and product labeling variability is a documented safety concern. Anticancer potential has been demonstrated in preclinical models (colorectal, liver cancer) but lacks clinical validation. CBD inhibits CYP3A4 and CYP2C19, creating clinically significant drug interaction risk requiring monitoring.